Clinical Trial Detail

NCT ID NCT02138812
Title Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bayer
Indications

Advanced Solid Tumor

triple-receptor negative breast cancer

Therapies

BAY1161909 + Paclitaxel

Age Groups: adult

No variant requirements are available.